


Open Access Article

 <https://doi.org/10.55463/issn.1674-2974.50.3.2>

CRP-Albumin Ratio Predicts in Hospital Survival of Infected COVID-19 Patient: Study in South Kalimantan, Indonesia

Haryati Haryati¹, Fidyah Rahmadhany Arganita¹, Mohamad Isa¹, Ali Assagaf¹, Eko Suhartono²,
Muhammad Nor¹

¹ Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia

² Department of Medical Chemistry/Biochemistry, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia

Received: January 5, 2023 ▪ Review: February 1, 2023 ▪ Accepted: March 6, 2023 ▪ Published: March 31, 2023

Abstract: Until the end of 2022, Indonesia had a case fatality rate (CFR) of 2.4% in COVID-19, higher than the global CFR of 1%. South Kalimantan, as one province in Indonesia, had CFR reached 2.9%. Improved treatment options and a better understanding of prognostic markers may reduce case fatality. Because of that, we decided to analyze CRP, albumin, and CRP-Albumin Ratio as prognostic markers in COVID-19. We conducted a retrospective study of 980 COVID-19 patients at Ulin Hospital Banjarmasin. The demographic data of the patients were analyzed and separated into two groups (survivors and non-survivors). We found that age, sex, and comorbidities such as hypertension, diabetes mellitus, and obesity correlated with mortality. CRP, albumin, and CRP-Albumin Ratio also correlated with mortality ($p < 0.001$) with an OR of 1.011, 0.468, and 1.032 respectively using univariate analysis. On multivariate analysis, we found that CRP, albumin, and CRP-Albumin Ratio are independent prognostic markers for mortality. ROC curve analysis shows that the CRP cut-off point was $> 61,2$ (sensitivity 70,2%, specificity 67,9%) with AUC 0.750 ($p < 0.001$) in predicting mortality. For the albumin, the cut-off point was $< 3,25$ (sensitivity 64,6%, specificity 54,1%) with AUC 0.628 ($p < 0.001$). Furthermore, in the CAR, the cut-off point was $> 26,2$ (sensitivity 62,4%, specificity 77,7%) with AUC 0.753 ($p < 0.001$). In conclusion, our study found that CRP, albumin, and CRP-Albumin ratio had a significant connection with mortality, with CRP-albumin ratio being a better predictor. It could be a substantial predictor of mortality in hospitalized COVID-19 patients, which is very easy and cheap.

Keywords: Covid-19, mortality, prognostic markers, CRP-albumin ratio, Indonesia.

协调研究计划-白蛋白比值预测受感染新冠肺炎 患者的医院存活率：在印度尼西亚 南加里曼丹进行的研究

摘要：到 2022 年底，印度尼西亚的新冠肺炎病死率(病死率)为 2.4%，高于全球 1% 的病死率。南加里曼丹作为印度尼西亚的一个省份，病死率达到 2.9%。改进治疗方案和更好地了解预后标志物可能会降低病死率。因此，我们决定分析协调研究计划、白蛋白和协调研究计划-白蛋白比率作为新冠肺炎的预后标志物。我们对马辰乌林医院的 980 名新冠肺炎患者进行了回顾性研究。分析患者的人口统计数据并将其分为两组（幸存者和非幸存者）。我们发现

年龄、性别和高血压、糖尿病和肥胖等合并症与死亡率相关。协调研究计划、白蛋白和协调研究计划-白蛋白比率也与死亡率相关($p < 0.001$)，单变量分析的或者分别为 1.011、0.468 和 1.032。在多变量分析中，我们发现协调研究计划、白蛋白和协调研究计划-白蛋白比率是死亡率的独立预后标志物。ROC曲线分析表明，协调研究计划截止点 $> 61,2$ (敏感性 70,2%，特异性 67,9%)，AUC 0.750 ($p < 0.001$) 预测死亡率。对于白蛋白，截止点为 < 3.25 (灵敏度 64.6%，特异性 54.1%)，AUC 为 0.628 ($p < 0.001$)。此外，在车中，截止点为 > 26.2 (灵敏度 62.4%，特异性 77.7%)，AUC 为 0.753 ($p < 0.001$)。总之，我们的研究发现协调研究计划、白蛋白和协调研究计划-白蛋白比率与死亡率有显著联系，协调研究计划-白蛋白比率是更好的预测因子。它可能是住院新冠肺炎患者死亡率的重要预测指标，这非常容易且便宜。

关键词：新冠肺炎、死亡率、预后标志物、协调研究计划-白蛋白比率、印度尼西亚。

1. Introduction

World Health Organization (WHO) declared Coronavirus Disease-2019 (COVID-19) a pandemic on March 11, 2020, and it caused widespread death. Until the end of 2022, Indonesia had a case fatality rate (CFR) of 2.4%, higher than the global CFR of 1%. South Kalimantan, as one province in Indonesia, had CFR reached 2.9% [1]. Since the onset of the pandemic, studies have revealed a considerable rise in death due to infections unrelated to COVID-19 [2]. The facts illustrate the pandemic's far-reaching impact, which extends beyond the mortality attributable to SARS-CoV-2. Some current statistics suggest that case fatality rates are decreasing regardless of confounding factors [3]. According to the study, improved treatment options and a better understanding of prognostic markers may reduce case fatality.

Biochemical markers C-reactive protein (CRP), D-dimer, albumin, and ferritin are widely used to determine prognosis [4-6]. Previous research has shown that uncontrolled inflammation is one of the most significant contributors to the COVID-19 disease's severity. CRP, one of the most often used inflammation indicators, has been reported to be associated with an illness with a severe condition. CRP is a positive acute-phase reactant, and it has been shown that elevated CRP levels relate to uncontrolled inflammation, a dire prognosis, and the severity of the disease [7].

The dietary status of patients influences their immunity, whereas malnutrition weakens the immune system and increases vulnerability to infection. Hypoalbuminemia mainly reflects nutritional status, but it has also been linked to the severity of COVID-19 [8]. Albumin is a negative acute-phase reactant, and low albumin levels have been linked to increased mortality and morbidity in coronavirus and numerous

other serious disorders. CRP elevation and hypoalbuminemia have been used frequently in research predicting the outcome of COVID-19 infection. It has been observed, however, that the CRP-Albumin Ratio (CAR) is a more accurate predictor of outcome in critical conditions such as sepsis and cancer, as well as in COVID-19 infection [9-12]. The CRP-Albumin ratio (CAR) is a recently defined metric indicating the ratio of a positive acute-phase reactant to a negative acute-phase reactant. It is a simultaneous indicator of both the inflammatory and nutritional states [13, 14].

However, it is essential to do more research to fully understand the relationship between albumin, CRP, and mortality in COVID-19. In addition, using the CRP-Albumin Ratio as a prognostic marker in COVID-19 may vary depending on the specific patient population and clinical setting. As a result, we decided to conduct this study to look into the effect of CAR levels on admission concern mortality in hospitalized COVID-19 patients in Indonesia, particularly in the provinces of South Kalimantan.

2. Materials and Methods

The study was to be conducted retrospectively at Ulin Hospital Banjarmasin in South Kalimantan, Indonesia. The ethical committee approved the study (No. 20/11-Reg Riset/RSUDU/23). The research involved all patients in the hospital between March 2020 and December 2021 who had positive COVID-19 PCR testing, was hospitalized in the isolation unit, aged > 18 , and had CRP and albumin testing when admitted. The patients excluded from this study are those with incomplete medical records or discharged by their own will. Totally 980 patient files were collected. The patients were separated into two groups: those who survived and those who did not.

Age, gender, comorbidities, number of comorbidities, the severity of illness, and body mass index (BMI) are demographic characteristics. The patients' blood test parameters, including albumin and C-reactive protein (CRP) on the first day of admission, were compared in terms of survival. CAR was calculated by dividing the CRP level on the first day of hospitalization by the albumin level. Categorical variables are presented as frequency and percentage. Continuous variables were tested for distribution using the Kolmogorov–Smirnov. The Mann–Whitney U test was performed in analyzing independent quantitative data. In examining independent qualitative data, the chi-square test was applied, and Fisher's Test was used if the chi-square test requirements were not met. With the use of ROC curve, the effect level and cut-of/f value were analyzed. The magnitude of the effect was assessed using univariate and multivariate with forward likelihood ratio logistic regression. A P value < 0.05 is considered statistically significant. SPSS 28.0 was used to conduct data analysis.

3. Result

In this retrospective study, we collected 980

patients' data, with 778 survivors, whereas 205 were non-survivors. The median age of the non-survivors was higher than the survivor's group ($p < 0.001$). There was also a difference in terms of gender distribution ($p = 0.014$).

Comorbidities such as hypertension, diabetes mellitus, and obesity correlate with the survivability of COVID-19 patients ($p = 0.004$, 0.001 , and 0.042 , respectively), and the number of comorbidities in the patients also play a significant role in survivability ($p < 0.001$). The severity of COVID-19 also affects the outcomes of patients ($p < 0.001$). The detailed information is listed in Table 1.

From Table 2, we can see that the non-survivor group had significantly higher CRP ($p < 0.001$), while the albumin was lower ($p < 0.001$). Because of that, the CRP-Albumin Ratio (CAR) was higher in the non-survivor group ($p < 0.001$).

The univariate analysis showed that CRP, Albumin, and CRP-Albumin Ratio (CAR) significantly correlated with mortality in COVID-19. In contrast, multivariate analysis identified that CRP, Albumin, and CAR are independent prognostic markers for mortality (Table 3).




Fig. 1 The schematic pathway of collecting samples and analysis (Elaborated by the authors)

Table 1 Demographic characteristics of patients hospitalized with the diagnosis of COVID-19 in survivors and non-survivors groups (Elaborated by the authors)

Variable	All patients (n = 980)	Survivors (n = 775)	Non-Survivors (n = 205)	p
Age, median (IQR), year	54 (44-62)	52 (43-60)	58 (49.5-65)	< 0.001*
- Male	54 (44-62)	53(43-61)	60(49-66)	< 0.001*
- Female	53 (43-61)	52(42-60)	57(49-64)	0.001*
Sex, no (%)				0.014 ^a
- Male	542 (55.3)	413 (42.1)	129 (13.2)	
- Female	438 (44.7)	362 (36.9)	76 (7.8)	
Comorbidities, no (%)				
- Hypertension	446 (45.5)	334 (34.1)	112 (11.4)	0.004 ^a
- Diabetes Mellitus	323 (33)	235 (24)	87 (9)	0.001 ^a
- Chronic Kidney Disease	102 (10.4)	74 (7.6)	28 (2.9)	0.095 ^a
- Cardiovascular disease	80 (8.1)	60 (6.1)	20 (2.0)	0.389 ^a
- Stroke	39 (4)	30 (3.1)	9 (0.9)	0.841 ^a

Continuation of Table 1

-	Malignancy	8 (0.8)	6 (0.6)	2 (0.2)	0.676 ^b
-	Hepatitis B	11 (1.1)	6 (0.6)	5 (0.5)	0.059 ^a
-	Lung tuberculosis	33 (3.4)	24 (2.4)	9 (0.9)	0.383 ^a
-	COPD	4 (0.4)	3 (0.3)	1 (0.1)	1.000 ^b
-	Asthma	27 (2.8)	21 (2.1)	6 (0.6)	1.000 ^a
-	Obesity	478 (48.8)	365(37.2)	113 (11.5)	0.042 ^a
Number of Comorbidities, no (%)					< 0.001 ^a
-	0	172 (17.6)	159 (16.2)	13 (1.3)	
-	1	330 (33.7)	262 (26.7)	68 (6.9)	
-	2	262 (26.7)	203 (20.7)	59 (6.0)	
-	≥ 3	216 (22)	151 (15.4)	65 (6.6)	
The severity of illness, no (%)					< 0.001 ^a
-	Mild	95 (9.7)	92 (9.4)	3 (0.3)	
-	Moderate	242 (24.7)	236 (24.1)	6 (0.6)	
-	Severe	162 (16.5)	148 (15.1)	14 (1.4)	
-	Critically ill	481 (49.1)	299 (30.5)	182 (18.6)	

* Mann-Whitney U test, ^a Pearson's chi-squared test, ^b Fisher exact test

Table 2 Laboratorium characteristics of patients hospitalized with the diagnosis of COVID-19 in survivors and non-survivors groups (Elaborated by the authors)

Parameter	All patients (n = 980)	Survivors (n = 775)	Non-Survivors (n = 205)	p
CRP, median (IQR)	45.5 (13-98.9)	33.8 (10.5 -80.5)	105.5 (48-187.7)	< 0.001*
Albumin, median (IQR)	3.4 (3.0-3.8)	3.5 (3.1-3.9)	3.2 (2.8 -3.5)	< 0.001*
CRP-Albumin Ratio, median (IQR)	13.3 (3.9-31.5)	10.5 (2.9-23.3)	33.9 (15.2-58.6)	< 0.001*

* Mann-Whitney U test

Table 3 Univariate and multivariate analysis for CRP, albumin, and CRP-albumin ratio (Elaborated by the authors)

Variables	Univariate			Multivariate		
	OR	95% CI	P	OR	95% CI	P
CRP	1.011	1.009 - 1.013	< 0.001	1.021	1.011-1.031	< 0.001
Albumin	0.468	0.355 - 0.618	< 0.001	0.498	0.323-0.768	0.002
CRP-Albumin Ratio	1.032	1.026 -1.038	< 0.001	0.968	0.938-0.998	0.035

Table 4 Optimum cut-off points* of CRP, albumin and CRP/albumin ratio in predicting mortality (Elaborated by the authors)

	Cut of Point	Sens (%)	Spec (%)	PPV (%)	NPV (%)	AUC	Youden's Index	P Value
CRP	≥ 61.2	70.2	67.9	20.9	79	0.750	0.381	< 0.001
Albumin	≤ 3.25	64.6	54.1	23.6	80.8	0.628	0.188	< 0.001
CRP-Albumin Ratio	≥ 26.2	62.4	77.7	21.3	79.2	0.753	0.401	< 0.001




Fig. 2 The ROC curve of CRP and CRP-albumin ratio for mortality (Elaborated by the authors)




Fig. 3 The ROC curve of albumin for mortality (Elaborated by the authors)

ROC curve analysis in Fig. 2 and 3 shows that the CRP cut-off point was > 61,2 (sensitivity 70,2%, specificity 67,9%) with AUC 0.750 (p < 0.001) in predicting mortality. For the albumin, the cut-off point was < 3,25 (sensitivity 64,6%, specificity 54,1%) AUC 0.628 (p < 0.001). Furthermore, in the CAR, the cut-off point was > 26,2 (sensitivity 62,4%, specificity 77,7%) with AUC 0.753 (p < 0.001).

4. Discussion

We reported the baseline demographic and laboratory information of our COVID-19 patients in this study. First, we found that age correlated with mortality (p < 0.001). Aging can have various effects on the human body and the immune system [15]. Lung muscular atrophy is expected in the elderly. Airway clearance, lung reserve, and defense barrier function were also reduced [16]. According to one study, every five years of age increased the mortality rate by 1.55 times [17]. Another result that we found is that gender also affects mortality. Males tend to have higher mortality (p < 0.014). As we know, the Centers for Disease Control and Prevention (CDC) already

reported that 54% of deaths by COVID-19 were male [18]. It stated that males had higher angiotensin-converting enzyme 2 (ACE2) expression, which made the male patients more at risk for SARS-CoV-2 infections and poor clinical outcomes [19]. It is also hypothesized that female patients may have a slower progression of SAR-CoV-2 infection and less severe outcome conditions due to x-linked heterozygous alleles called sex dimorphism [20]. For the comorbidities, we found that hypertension, diabetes mellitus, and obesity had higher mortality ($p = 0.004$, 0.001 , and 0.042 , respectively). The number of comorbidities also affect mortality ($p < 0.001$). The relationships between hypertension and COVID-19 are not fully discovered, but they could be related to endothelial dysfunction and renin-angiotensin system (RAS) imbalance. It stated that RAS axis activation parallels non-conventional axis down-regulation in COVID-19, leading to a severe clinical condition. The endothelial dysfunction related to hypertension also plays a role in the proinflammatory state and causes a higher level of chemokines, cytokines, and tumor necrosis factor- α in COVID-19 [21]. In diabetes mellitus patients, the rapid progression of diseases and severe clinical outcomes may be due to hyperglycemia affecting immune function. It also causes macrovascular complications [22]. Increased blood glucose also promotes lung fibrosis, chronic inflammation, and inflammatory cytokine release [23]. The last one, for obesity comorbidities, generally has an impaired innate and adaptive immune response. People with obesity tend to have chronic low-grade inflammation, which leads to abrupt systemic metabolic alteration (higher levels of leptin and lower adiponectin). Obesity also enhanced the production of several proinflammatory cytokines. This condition will lead to poor outcomes of COVID-19 [24]. The mortality rate of COVID-19 patients also increased if the patient had more than one comorbid [25].

For this study, we focus on the laboratory results on CRP and albumin. We also counted the CRP-Albumin Ration (CAR) and analyzed with mortality in COVID-19. CRP is an acute-phase pentameric protein. It is synthesized in the liver, and induced by IL-6, in response to inflammation. It is a crucial player in recognizing and clearance of pathogens [26]. Although albumin is the major protein in human plasma, it accounts for less than a quarter of the plasma oncotic pressure. It is produced by the liver and fulfills multiple crucial functions. Albumin distributes many molecules through the bloodstream, acts as an antioxidant and suppresses platelet aggregation. It is essential in numerous processes, particularly inflammation [27].

In SARS-CoV-2 infection, inflammation plays a central role. This virus can generate a broad spectrum of clinical manifestations [28]. SARS-CoV-2 causes the destruction of lymphocytes, making lymphopenia conditions and serum albumin decrease while inducing

an increase in CRP and ferritin [29]. In our study, we found that CRP, albumin, and CAR correlated with mortality ($p < 0.001$). Let us break down the mechanism one by one. CRP is indispensable for the identification of foreign compounds. In inflammatory or infectious disorders, the adaptive immune system is activated by interaction with foreign molecules. CRP is also a scavenger for damaged membranes, decaying nuclear material, and autoantigens. Because of that, the CRP level in serum is directly proportional to disease severity and outcomes [30]. For albumin, recent studies show that COVID-19 patients with hypo albumin had a poor prognosis compared with patients with normal albumin [31, 32]. Hypothesized mechanisms for hypoalbuminemia during sepsis could explain the decrease in albumin. Inflammatory activities that generate cytokines (IL-1, IL-6, and TNF-) result in hypoalbuminemia due to decreased albumin synthesis and increased hormone catabolism. During severe SARS-CoV-2 infection, inflammatory processes and mediator levels are enhanced. In severe inflammatory circumstances, there is an increase in capillary permeability, which may contribute to hypoalbuminemia due to an increase in interstitial albumin release and an increase in filtration rate. Reduced albumin levels may therefore indicate a robust inflammatory response and, in more advanced cases, systemic involvement comparable to that seen in sepsis [33]. CRP/Albumin Ratio (CAR) is already been utilized as a prognostic biomarker in various disorders. CRP and albumin are both generated in the liver and regulated by IL-6. CRP is positively affected by this mechanism, and albumin is negatively affected. Due to this, the ratio between these can be used to measure disease severity. In COVID-19 cases, it has been established that a greater CAR correlates with death [34]. Then in univariate analysis, CRP, albumin, and CAR had OR 1.011, 0.468, and 1.032, respectively, with $p < 0.001$. These data show that while CRP and albumin can be used as prognostic factors, CAR has proven to be a better tool. However, when we analyzed with multivariate, we found that CRP was a better independent factor for mortality (OR 1.021 and $p < 0.001$). Although if we look at the ROC curve, the CAR has a better AUC than CRP (0.753 vs. 0.750). It resembles a study from Lucijanac et al. [37], which calculates the 30-day survival of COVID-19 patients using CAR. [34] Another study that supports our result is [35]. In that study, not only the CAR has better AUC, but it also has better sensitivity and specificity rather than CRP or albumin alone.

The CRP, albumin, and CAR cut-off that correlates with mortality in our study were > 61.2 , $< 3,25$, and > 26.2 , respectively. In another study, the cut-off was $> 33,9$, $< 3,8$, and $> 8,9$, respectively [35]. The other study showed that the cut-off CAR value was reported to be 5.4 [36]. We propose that the disparity in cut-off values can be attributed to differences in patient

characteristics and the diverse methodology used in the studies.

Our research has limitations. It is a retrospective and single-center study, resulting in inherent limitations. Evidence suggesting a connection between CAR and mortality might be strengthened if prospective studies were conducted across multiple centers. Additionally, our research was carried out in a province that only covers a small geographical area, making it impossible to generalize our findings nationally or internationally. Nevertheless, since our findings correlated with those of other research, it would indicate that our findings are consistent with the findings of the larger community of COVID-19 patients.

5. Conclusion

CRP and albumin are already been used as inflammation markers in COVID-19. Many studies have proved their relationship with disease severity. However, studies about their correlation with mortality still need to be completed. There are already studies on the CRP-albumin ratio correlation with mortality in COVID-19, but it's still minimal. That's why our study can help other researchers in their research on CRP and albumin.

In conclusion, our study found that CRP, albumin, and CRP-Albumin ratio had a significant connection with mortality, with CRP-albumin ratio being a better predictor. It could be a substantial predictor of mortality in hospitalized COVID-19 patients. We can estimate the probability of death based on the CAR level at admission, which is very easy and cheap, especially in countries with limited sources such as Indonesia.

References

[1] KEMENKES. Situasi Terkini Perkembangan Coronavirus Disease (COVID-19) 25 Januari 2022. *Media Informasi Resmi Terkini Penyakit Infeksi Emerging*, 2023. <https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-25-januari-2023>

[2] WOOLF S. H., CHAPMAN D. A., SABO R. T., WEINBERGER D. M., and HILL L. Excess deaths from COVID-19 and other causes. *JAMA*, 2020, 324(5): 510-513. <http://jamanetwork.com/article.aspx?doi=10.1001/jama.2020.11787>

[3] HORWITZ L. I., JONES S. A., CERFOLIO R. J., FRANCOIS F., GRECO J., RUDY B., and PETRILLI C. M. Trends in COVID-19 risk-adjusted mortality rates. *Journal of Hospital Medicine*, 2021, 16(2): 90-92. <https://doi.org/10.12788/jhm.3552>

[4] HUANG I., PRANATA R., LIM M. A., OEHADIAN A., and ALISJAHBANA B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis. *Therapeutic Advances in Respiratory Disease*, 2020, 14. <https://doi.org/10.1177/1753466620937175>

[5] VIOLI F., CANGEMI R., ROMITI G. F., CECCARELLI G., OLIVA A., ALESSANDRI F., PIRRO M., PIGNATELLI P., LICHTNER M., CARRARO A., CIPOLLONE F., D'ARDES D., PUGLIESE F., and MASTROIANNI C. M. Is albumin predictor of mortality in COVID-19? *Antioxidants & Redox Signaling*, 2021, 35: 139-142. <https://doi.org/10.1089/ars.2020.8142>

[6] HARYATI H., ISA M., ASSAGAF A., NURRASYIDAH I., KUSUMAWARDHANI E., SUHARTONO E., and ARGANITA F. R. Clinical and Laboratory Features of COVID-19 in Ulin Referral Hospital of South Kalimantan: Predictors of Clinical Outcome. *Journal of Tropical Life Science*, 2021, 11(3): 299-307. <https://doi.org/10.11594/jtls.11.03.06>

[7] PONTI G., MACCAFERRI M., RUINI C., TOMASI A., and OZBEN T. Biomarkers associated with COVID-19 disease progression. *Critical Reviews in Clinical Laboratory Sciences*, 2020, 57: 389-399. <https://doi.org/10.1080/10408363.2020.1770685>

[8] AZIZ M., FATIMA R., LEE-SMITH W., and ASSALY R. The association of low serum albumin level with severe COVID-19: A systematic review and meta-analysis. *Critical Care* 2020, 24: 255. <https://doi.org/10.1186/s13054-020-02995-3>

[9] KARABAĞ Y., ÇAĞDAŞ M., RENCUZOGULLARI I., KARAKOYUN S., ARTAÇ İ., İLİŞ D., YESİN M., ÇAĞDAŞ Ö. S., ALTINTAŞ B., BURAK C., and TANBOĞA H. I. Usefulness of the C-Reactive protein/albumin ratio for predicting no-reflow in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. *European Journal of Clinical Investigation*, 2018, 48: e12928. <https://doi.org/10.1111/eci.12928>

[10] FAN Z, FAN K, GONG Y, HUANG Q, YANG C, CHENG H, JIN K., NI Q., YU X., LUO G., and LIU C. The CRP-Albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer. *Cancer Management and Research*, 2019, 11: 8781-8788. <https://doi.org/10.2147%2FCMAR.S211363>

[11] SAYLIK F., AKBULUT T., and KAYA S. Can C-reactive protein to albumin ratio predict in-hospital death rate due to COVID-19 in patients with hypertension? *Angiology*, 2021, 72: 947-952. <https://doi.org/10.1177/00033197211012145>

[12] GÜNEY B.Ç., TAŞTAN Y.Ö., DOĞANTEKİN B., SERİNDAĞ Z., YENİÇERİ M., ÇİÇEK V., KILIÇ Ş., ŞEKER M., ÇINAR T., HAYIROĞLU M. İ., and KAPLAN M. Predictive value of CAR for in-hospital mortality in patients with COVID-19 pneumonia: A retrospective cohort study. *Archives of Medical Research*, 2021, 52: 554-560. <https://doi.org/10.1016/j.arcmed.2021.02.006>

[13] MOON J.S., AHN S.S., PARK Y.B., LEE S.K., and LEE S.W. C-Reactive protein to serum albumin ratio is an independent predictor of all-cause mortality in patients with ANCA-associated vasculitis. *Yonsei Medical Journal*, 2018, 59: 865-867. <https://doi.org/10.3349/ymj.2018.59.7.865>

[14] OH T.K., SONG I.A., and LEE J.H. Clinical usefulness of C-reactive protein to albumin ratio in predicting 30-day mortality in critically ill patients: A retrospective analysis. *Scientific Reports*, 2018, 8: 14977. <https://doi.org/10.1038/s41598-018-33361-7>

[15] NIKOLICH-ŽUGIČ J. The twilight of immunity: emerging concepts in aging of the immune system. *Nature Immunology*, 2018, 19(1): 10-19.

<https://doi.org/10.1038/s41590-017-0006-x>

[16] MORI H., OBINATA H., MURAKAMI W., TATSUYA K., SASAKI H., MIYAKE Y., TANIGUCHI Y., OTA S., YAMAGA M., SUYAMA Y., and TAMURA K. Comparison of COVID-19 disease between young and elderly patients: Hidden viral shedding of COVID-19. *Journal of Infection and Chemotherapy*, 2021, 27(1): 70-75. <https://doi.org/10.1016/j.jiac.2020.09.003>

[17] RECINELLA G., MARASCO G., SERAFINI G., MAESTRI L., BIANCHI G., FORTI P., and ZOLI M. Prognostic role of nutritional status in elderly patients hospitalized for COVID-19: a monocentric study. *Aging Clinical and Experimental Research*, 2020, 32: 2695-2701. <https://doi.org/10.1007/s40520-020-01727-5>

[18] CENTERS FOR DISEASE CONTROL AND PREVENTION. COVID-19. CDC. <https://www.cdc.gov/coronavirus/2019-ncov/index.html>

[19] LA VIGNERA S., CANNARELLA R., CONDORELLI R.A., TORRE F., AVERSA A., and CALOGERO A.E. Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. *International Journal of Molecular Sciences*, 2020, 21(8): 2948. <https://doi.org/10.3390/ijms21082948>

[20] GEMMATI D., BRAMANTI B., SERINO M.L., SECCHIERO P., ZAULI G., and TISATO V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? *International Journal of Molecular Sciences*, 2020, 21(10): 3474. <https://doi.org/10.3390/ijms21103474>

[21] MUHAMAD S. A., UGUSMAN A., KUMAR J., SKIBA D., HAMID A. A., and AMINUDDIN A. COVID-19 and hypertension: the what, the why, and the how. *Frontiers in Physiology*, 2021, 3, 12: 665064. <https://doi.org/10.3389/fphys.2021.665064>

[22] LIM S., BAE J.H., KWON H.S., and NAUCK M.A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nature Reviews Endocrinology*, 2021, 17(1): 11-30. <https://doi.org/10.1038/s41574-020-00435-4>

[23] KOLAHIAN S., LEISS V., and NÜRNBERG B. Diabetic lung disease: fact or fiction? *Reviews in Endocrine and Metabolic Disorders*, 2019, 20: 303-319. <https://doi.org/10.1007/s11154-019-09516-w>

[24] ABU-FARHA M., AL-MULLA F., THANARAJ T. A., KAVALAKATT S., ALI H., ABDUL GHANI M., and ABUBAKER J. Impact of diabetes in patients diagnosed with COVID-19. *Frontiers in Immunology*, 2020, 11: 576818. <https://doi.org/10.3389/fimmu.2020.576818>

[25] DJAHARUDDIN I., MUNAWWARAH S., NURULITA A., ILYAS M., TABRI N.A., and LIHAWA N. Comorbidities and mortality in COVID-19 patients. *Gaceta Sanitaria*, 2021, 35: 530-532. <https://doi.org/10.1016/j.gaceta.2021.10.085>

[26] BOUAYED M. Z., LAARIBI I., CHATAR C. E., BENAINI I., BOUAZZAOU M. A., OUJIDI Y., BERRICHI S., EL AIDOUNI G., BKIYAR H., ABDA N., and HOUSNI B. C-Reactive Protein (CRP): A poor prognostic biomarker in COVID-19. *Frontiers in Immunology*, 2022, 13. <https://doi.org/10.3389/fimmu.2022.1040024>

[27] ABDEEN Y., KAAKO A., AHMAD AMIN Z.,

MUHANNA A., JOSEFINE FROESSL L., ALNABULSI M., OKEH A., and MILLER R. A. The prognostic effect of serum albumin level on outcomes of hospitalized COVID-19 patients. *Critical Care Research and Practice*, 2021, 2021: 9963274. <https://doi.org/10.1155/2021/9963274>

[28] MEHTA P., MCAULEY D.F., BROWN M., SANCHEZ E., TATTERSALL R.S., and MANSON J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet*, 2020, 395(10229): 1033-1034. [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)

[29] UZUM Y., & TURKKAN E. Predictivity of CRP, Albumin, and CRP to Albumin Ratio on the Development of Intensive Care Requirement, Mortality, and Disease Severity in COVID-19. *Cureus*, 2023, 15(1). <https://doi.org/10.7759/cureus.33600>

[30] FAZAL M. C-reactive protein a promising biomarker of COVID-19 severity. *Korean Journal of Clinical Laboratory Science*, 2021, 53(3): 201-207. <https://doi.org/10.15324/kjcls.2021.53.3.201>

[31] HUANG J., CHENG A., KUMAR R., FANG Y., CHEN G., ZHU Y., and LIN S. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and comorbidity. *Journal of Medical Virology*, 2020, 92(10): 2152-2158. <https://doi.org/10.1002/jmv.26003>

[32] MINATOGUCHI S., NOMURA A., IMAIZUMI T., SASAKI S., OZEKI T., UCHIDA D., KAWARAZAKI H., SASAI F., TOMITA K., SHIMIZU H., and FUJITA Y. Low serum albumin as a risk factor for infection-related in-hospital death among hemodialysis patients hospitalized on suspicion of infectious disease: a Japanese multicenter retrospective cohort study. *Renal Replacement Therapy*, 2018, 4(1): 30. <https://doi.org/10.1186/s41100-018-0173-8>

[33] TURCATO G., ZABOLI A., KOSTIC I., MELCHIORETTO B., CICCARIELLO L., ZACCARIA E., OLIVATO A., MACCAGNANI A., PFEIFER N., and BONORA A. Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study. *Emergency Medicine Journal*, 2022, 39(1): 63-69. <http://dx.doi.org/10.1136/emered-2020-210081>

[34] LUCIJANIĆ M., STOJIC J., ATIC A., ČIKARA T., OSMANI B., BARIŠIĆ-JAMAN M., ANDRILOVIĆ A., BISTROVIĆ P., VRKLJAN A. Z., LAGANČIĆ M., MILOŠEVIĆ M., VUKOJA I., ĐEREK L., LUCIJANIĆ T., and ŽIVKOVIĆ N. P. Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients: Data on 2309 patients from a tertiary center and validation in an independent cohort. *Wiener klinische Wochenschrift*, 2022, 134(9-10): 377-384. <https://doi.org/10.1007/s00508-021-01999-5>

[35] EL-SHABRAWY M., ALSADIK M. E., EL-SHAFAEI M., ABDELMOATY A. A., ALAZZOUNI A. S., ESAWY M. M., and SHABANA M. A. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. *The Egyptian Journal of Bronchology*, 2021, 15: 1-7. <https://doi.org/10.1186/s43168-021-00054-1>

[36] KALABIN A., MANI V. R., VALDIVIESO S. C., and DONALDSON B. Does C reactive protein/Albumin ratio have prognostic value in patients with COVID-19. *The Journal of Infection in Developing Countries*, 2021, 15(08): 1086-1093. <https://doi.org/10.3855/jidc.14826>

[37] LUCIJANIĆ M., STOJIC J., ATIC A., ČIKARA T., OSMANI B., BARIŠIĆ-JAMAN M., ANDRILOVIĆ A.,

BISTROVIĆ P., VRKLJAN A. Z., LAGANČIĆ M., MILOŠEVIĆ M., VUKOJA I., ĐEREK L., LUCIJANIĆ T., and ŽIVKOVIĆ N. P. Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients. *Wiener klinische Wochenschrift*, 2022, 134: 377–384. <https://doi.org/10.1007/s00508-021-01999-5>

参考文献:

[1] 凯门克斯. 冠状病毒病 (新冠肺炎) 的发展现状2022年1月25日. 新发传染病的最新官方信息媒体, 2023. <https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-25-januari-2023>

[2] WOOLF S. H., CHAPMAN D. A., SABO R. T., WEINBERGER D. M., 和 HILL L. 新冠肺炎和其他原因导致的死亡人数过多. 美国医学会杂志, 2020年, 324(5) : 第 510-513 页 . <http://jamanetwork.com/article.aspx?doi=10.1001/jama.2020.11787>

[3] HORWITZ L. I., JONES S. A., CERFOLIO R. J., FRANCOIS F., GRECO J., RUDY B., 和 PETRILLI C. M. 新冠肺炎风险调整后死亡率趋势. 医院医学杂志, 2021年, 16(2) : 第 90-92 页 . <https://doi.org/10.12788/jhm.3552>

[4] HUANG I., PRANATA R., LIM M. A., OEHADIAN A., 和 ALISJAHBANA B. 严重冠状病毒病 新冠肺炎中的 C反应蛋白、降钙素原、丁二聚体和铁蛋白: 一项荟萃分析. 呼吸系统疾病的治疗进展, 2020, 14. <https://doi.org/10.1177/1753466620937175>

[5] VIOLI F., CANGEMI R., ROMITI G. F., CECCARELLI G., OLIVA A., ALESSANDRI F., PIRRO M., PIGNATELLI P., LICHTNER M., CARRARO A., CIPOLLONE F., D'ARDES D., PUGLIESE F., 和 MASTROIANNI C. M. 白蛋白是 新冠肺炎死亡率的预测指标吗? 抗氧化剂和氧化还原信号, 2021年, 35 : 第 139-142 页. <https://doi.org/10.1089/ars.2020.8142>

[6] HARYATI H., ISA M., ASSAGAF A., NURRASYIDAH I., KUSUMAWARDHANI E., SUHARTONO E., 和 ARGANITA F. R. 南加里曼丹乌林转诊医院 新冠肺炎的临床和实验室特征: 临床结果的预测因子. 热带生命科学杂志, 2021年, 11(3) : 第 299-307 页. <https://doi.org/10.11594/jtls.11.03.06>

[7] PONTI G., MACCAFERRI M., RUINI C., TOMASI A., 和 OZBEN T. 与新冠肺炎疾病进展相关的生物标志物. 临床实验室科学的批判性评论, 2020, 57: 第 389-399 页 . <https://doi.org/10.1080/10408363.2020.1770685>

[8] AZIZ M., FATIMA R., LEE-SMITH W., 和 ASSALY R. 低血清白蛋白水平与严重 新冠肺炎的关联: 系统评价和荟萃分析. 重症监护 2020, 24 : 第 255 条 . <https://doi.org/10.1186/s13054-020-02995-3>

[9] KARABAĞ Y., ÇAĞDAŞ M., RENCUZOGULLARI I., KARAKOYUN S., ARTAÇ İ., İLİŞ D., YESİN M., ÇAĞDAŞ Ö. S., ALTINTAŞ B., BURAK C., 和 TANBOĞA H. I. C反应蛋白/白蛋白比率在预测经皮冠状动脉介入治疗的英石段抬高心肌梗死中无再流的有用性. 欧洲临床研究杂志, 2018年, 48 : 文章电子12928. <https://doi.org/10.1111/eci.12928>

[10] FAN Z, FAN K, GONG Y, HUANG Q, YANG C, CHENG H, JIN K., NI Q., YU X., LUO G., 和 LIU C. C 反应蛋白-白蛋白比率可预测晚期胰腺癌患者的生存率并监测化疗效果. 癌症管理与研究, 2019年, 11 : 第 8781-8788 页. <https://doi.org/10.2147%2FCMAR.S211363>

[11] SAYLIK F., AKBULUT T., 和 KAYA S. C 反应蛋白与白蛋白的比率能否预测高血压患者因新冠肺炎导致的院内死亡率? 血管学, 2021年, 72 : 第 947-952 页. <https://doi.org/10.1177/00033197211012145>

[12] GÜNEY B.Ç., TAŞTAN Y.Ö., DOĞANTEKİN B., SERİNDAĞ Z., YENİÇERİ M., ÇİÇEK V., KILIÇ Ş., ŞEKER M., ÇINAR T., HAYIROĞLU M. İ., 和 KAPLAN M. 曲线分析研究对 新冠肺炎肺炎患者住院死亡率的预测价值: 一项回顾性队列研究. 医学研究档案, 2021年, 52 : 第 554-560 页 . <https://doi.org/10.1016/j.arcmed.2021.02.006>

[13] MOON J.S., AHN S.S., PARK Y.B., LEE S.K., 和 LEE S.W. C反应蛋白与血清白蛋白的比率是抗中性粒细胞胞质抗体相关血管炎患者全因死亡率的独立预测因子. 延世医学杂志, 2018, 59: 第 865-867 页 . <https://doi.org/10.3349/ymj.2018.59.7.865>

[14] OH T.K., SONG I.A., 和 LEE J.H. C反应蛋白与白蛋白比率在预测危重患者 30 天死亡率方面的临床用途: 一项回顾性分析. 科学报告, 2018, 8: 文章 14977. <https://doi.org/10.1038/s41598-018-33361-7>

[15] NIKOLICH-ŽUGICH J. 免疫力的曙光: 免疫系统老化的新概念. 自然免疫学, 2018, 19(1) : 第 10-19 页. <https://doi.org/10.1038/s41590-017-0006-x>

[16] MORI H., OBINATA H., MURAKAMI W., TATSUYA K., SASAKI H., MIYAKE Y., TANIGUCHI Y., OTA S., YAMAGA M., SUYAMA Y., 和 TAMURA K. 青年和老年患者新冠肺炎疾病的比较: 新冠肺炎的隐性病毒脱落. 感染与化疗杂志, 2021年, 27(1) : 第 70-75 页. <https://doi.org/10.1016/j.jiac.2020.09.003>

[17] RECINELLA G., MARASCO G., SERAFINI G., MAESTRI L., BIANCHI G., FORTI P., 和 ZOLI M. 营养状况对因 新冠肺炎住院的老年患者的预后作用: 一项单中心研究. 老化临床和实验研究, 2020年, 32 : 第 2695-2701 页. <https://doi.org/10.1007/s40520-020-01727-5>

[18] 疾病预防与控制中心. 新冠肺炎. 疾病预防与控制中心 . <https://www.cdc.gov/coronavirus/2019-ncov/index.html>

- [19] LA VIGNERA S., CANNARELLA R., CONDORELLI R.A., TORRE F., AVERSA A., 和 CALOGERO A.E. 性别特异性 新冠肺炎死亡率：在激素调节的血管紧张素转换酶2表达、静脉血栓栓塞和维生素缺乏症丁的风险中。国际分子科学杂志, 2020年, 21(8) : 文章2948. <https://doi.org/10.3390/ijms21082948>
- [20] GEMMATI D., BRAMANTI B., SERINO M.L., SECCHIERO P., ZAULI G., 和 TISATO V. 新冠肺炎和个体遗传易感性/接受性：血管紧张素转换酶1/血管紧张素转换酶2基因、免疫、炎症和凝血的作用。与男性的单X染色体相比, 女性的双X染色体是否可以预防非典-冠状病毒-2? 国际分子科学杂志, 2020, 21(10): 文章3474. <https://doi.org/10.3390/ijms21103474>
- [21] MUHAMAD S. A., UGUSMAN A., KUMAR J., SKIBA D., HAMID A. A., 和 AMINUDDIN A. 新冠肺炎和高血压：是什么、为什么以及如何。生理学前沿, 2021年3月12日：文章665064. <https://doi.org/10.3389/fphys.2021.665064>
- [22] LIM S., BAE J.H., KWON H.S., 和 NAUCK M.A. 新冠肺炎和糖尿病：从病理生理学到临床管理。自然评论内分泌学, 2021年, 17(1)：第11-30页。 <https://doi.org/10.1038/s41574-020-00435-4>
- [23] KOLAHIAN S., LEISS V., 和 NÜRNBERG B. 糖尿病肺病：事实还是虚构? 内分泌和代谢紊乱评论, 2019年, 20：第303-319页。 <https://doi.org/10.1007/s11154-019-09516-w>
- [24] ABU-FARHA M., AL-MULLA F., THANARAJ T. A., KAVALAKATT S., ALI H., ABDUL GHANI M., 和 ABUBAKER J. 糖尿病对诊断为新冠肺炎的患者的影响。免疫学前沿, 2020, 11：文章576818. <https://doi.org/10.3389/fimmu.2020.576818>
- [25] DJAHARUDDIN I., MUNAWWARAH S., NURULITA A., ILYAS M., TABRI N.A., 和 LIHAWA N. 新冠肺炎患者的合并症和死亡率。卫生报, 2021年, 35：第530-532页。 <https://doi.org/10.1016/j.gaceta.2021.10.085>
- [26] BOUAYED M. Z., LAARIBI I., CHATAR C. E., BENAINI I., BOUAZZAOUI M. A., OUJIDI Y., BERRICHI S., EL AIDOUNI G., BKIYAR H., ABDA N., 和 HOUSNI B. C反应蛋白：新冠肺炎的不良预后生物标志物。免疫学前沿, 2022, 13. <https://doi.org/10.3389/fimmu.2022.1040024>
- [27] ABDEEN Y., KAAKO A., AHMAD AMIN Z., MUHANNA A., JOSEFINE FROESSL L., ALNABULSI M., OKEH A., 和 MILLER R. A. 血清白蛋白水平对住院新冠肺炎患者预后的影响。重症监护研究与实践, 2021, 2021: 9963274. <https://doi.org/10.1155/2021/9963274>
- [28] MEHTA P., MCAULEY D.F., BROWN M., SANCHEZ E., TATTERSALL R.S., 和 MANSON J.J. 新冠肺炎：考虑细胞因子风暴综合征和免疫抑制。柳叶刀, 2020年, 395(10229)：第1033-1034页。 [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)
- [29] UZUM Y., 和 TURKKAN E. C反应蛋白、白蛋白和C反应蛋白与白蛋白比率对新冠肺炎重症监护需求、死亡率和疾病严重程度发展的预测。库鲁斯, 2023, 15(1). <https://doi.org/10.7759/cureus.33600>
- [30] FAZAL M. C反应蛋白是新冠肺炎严重程度的有前途的生物标志物。韩国临床实验室科学杂志, 2021年, 53(3)：第201-207页。 <https://doi.org/10.15324/kjcls.2021.53.3.201>
- [31] HUANG J., CHENG A., KUMAR R., FANG Y., CHEN G., ZHU Y., 和 LIN S. 低白蛋白血症预测新冠肺炎的结果, 与年龄和合并症无关。医学病毒学杂志, 2020, 92(10): 第2152-2158页。 <https://doi.org/10.1002/jmv.26003>
- [32] MINATOGUCHI S., NOMURA A., IMAIZUMI T., SASAKI S., OZEKI T., UCHIDA D., KAWARAZAKI H., SASAI F., TOMITA K., SHIMIZU H., 和 FUJITA Y. 低血清白蛋白作为怀疑感染性疾病住院的血液透析患者感染相关院内死亡的危险因素：一项日本多中心回顾性队列研究。肾脏替代疗法, 2018年, 4(1)：第30条。 <https://doi.org/10.1186/s41100-018-0173-8>
- [33] TURCATO G., ZABOLI A., KOSTIC I., MELCHIORETTO B., CICCARIELLO L., ZACCARIA E., OLIVATO A., MACCAGNANI A., PFEIFER N., 和 BONORA A. 第一次急诊科评估时记录的新冠肺炎感染严重程度和白蛋白水平：一项多中心回顾性观察研究。急诊医学杂志, 2022年, 39(1)：第63-69页。 <http://dx.doi.org/10.1136/emmermed-2020-210081>
- [34] LUCIJANIĆ M., STOJIC J., ATIC A., CİKARA T., OSMANI B., BARIŠIĆ-JAMAN M., ANDRILOVIĆ A., BISTROVIĆ P., VRKLJAN A. Z., LAGANČIĆ M., MILOŠEVIĆ M., VUKOJA I., ĐEREK L., LUCIJANIĆ T., 和 ŽIVKOVIĆ N. P. C反应蛋白与白蛋白比值在2019年住院冠状病毒病患者中的临床和预后意义：来自三级中心的2309名患者的数据和在独立队列中的验证。维也纳临床周刊, 2022, 134(9-10): 第377-384页。 <https://doi.org/10.1007/s00508-021-01999-5>
- [35] EL-SHABRAWY M., ALSADIK M. E., EL-SHAFEI M., ABDELMOATY A. A., ALAZZOUNI A. S., ESAWY M. M., 和 SHABANA M. A. 白细胞介素6和C反应蛋白/白蛋白比率作为新冠肺炎严重性和死亡率的预测因子。埃及支气管学杂志, 2021年, 15：第1-7页。 <https://doi.org/10.1186/s43168-021-00054-1>
- [36] KALABIN A., MANI V. R., VALDIVIESO S. C., 和 DONALDSON B. C反应蛋白/白蛋白比值对新冠肺炎患者有预后价值吗? 发展中国家感染杂志, 2021年, 15(08)：第1086-1093页。 <https://doi.org/10.3855/jidc.14826>
- [37] LUCIJANIĆ M., STOJIC J., ATIC A., CİKARA T., OSMANI B., BARIŠIĆ-JAMAN M., ANDRILOVIĆ A., BISTROVIĆ P., VRKLJAN A. Z., LAGANČIĆ M., MILOŠEVIĆ M., VUKOJA I., ĐEREK L., LUCIJANIĆ T., and ŽIVKOVIĆ N. P. C反应蛋白与白蛋白比率在2019年

住院冠状病毒病(新冠肺炎)患者中的临床和预后意义。
维也纳临床周刊, 2022, 134: 377-384。
<https://doi.org/10.1007/s00508-021-01999-5>